网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
唑来膦酸注射液治疗61例骨质疏松疗效观察
作者:林智  
单位:湛江中心人民医院骨科
关键词:原发性骨质疏松症 唑来膦酸钠 疗效 
分类号:
出版年·卷·期(页码):2014··第二期(0-)
摘要:

【摘要】 目的 探讨唑来膦酸钠注射液(密固达)治疗原发性骨质疏松症的疗效 。方法 采用前瞻性研究的方法,将我院自2010年1月至2012年1间收治的骨质疏松症患者122例患者,按照随机配对原则分为治疗组和对照组,61对照组给予钙尔奇D片(含有钙和维生素D3)1片,1日/1次,疗程为1年,61例观察组在对照组的基础上给予唑来膦酸钠注射液5mg静滴,1年后,对两组患者治疗前后血钙,血磷和AKP的变化及腰椎、股骨颈、髋部的骨密度和临床疗效进行比较。结果 治疗组和对照组治疗前和治疗后1年,血钙、血磷及碱性磷酸酶(ALP)进行比较,血钙、血磷比较,差异无统计学意义(P>0.05), ALP的值进行比较,差异有统计学意义(P<0.05)。治疗组和对照组腰椎、股骨颈、大转子等处的骨密度进行比较,差异有统计学意义(P<0.05)。治疗组总有效率(显效+有效)为96.72%(59/61),对照组有效率为81.97%(50/61)。两组总有效率比较,差异有统计学意义(P<0.05)。 结论 唑来膦酸钠注射液治疗骨质疏松症疗效显著,安全、依从性好,是治疗骨质疏松症理想药物选择。

【Abstract】 Objective To explore effect observation on zoledronic acid injection treatment of primary osteoporosis.Methods By the prospective study method, according to the random matching principle, the 122 cases patients with osteoporosis divided into treatment group and control group from January 2010 to January 2012, control group (61 cases )was gave Caltrate(1 piece, one time/one day), treatment for 1 year; treatment group on the basis of control group were given zoledronic acid injection(5mg), after 1 year, before and after treatment ,the two groups with blood calcium, phosphorus, the change of blood ALP and lumbar, femoral neck, hip bone density and clinical curative effect were compared. Results Before treatment and after treatment 1 year, the blood calcium and blood phosphorus were compared, the difference was not statistically significant (P > 0.05), alkaline phosphatase (ALP)was compared, difference have statistical significance (P < 0.05). lumbar, femoral neck, hip bone density were compared, the difference was statistically significant (P < 0.05). total effective rate (powerfully + effective) of treatment group was 96.72% (59/61), effective rate of control group was 81.97% (50/61). Two groups of the total effective rate were compared, the difference was statistically significant (P < 0.05). Conclusion Effect observation on zoledronic acid for treatment of primary osteoporosis is distinct, safety, compliance, it is ideal choice for the treatment of osteoporosis.

参考文献:
服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 756431 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541